HepaPuff, an innovative handheld heparin nebuliser to prevent infection with SARS-CoV-2 and new emerging respiratory viruses.

(Hepa)Puff against new virus pandemics Researchers from the Amsterdam UMC and UvA, together with the company Medspray, will develop a Heparin hand nebulizer that not only protects against coronaviruses but also other viral respiratory infections. They combine an innovative hand nebulizer based on nanotech membrane chip technology with a broad spectrum virus inhibitor. The nebulizer will not only be tested on in vitro models but also in healthy volunteers in a controlled environment. Because clinically approved inhibitors and an existing new technology are used, the so-called HepaPuff can be brought onto the market quickly after completion of the project. HepaPuff will be an accessible and affordable prevention method against SARS-CoV-2 variants and possible new virus pandemics.